We Just Had An Epiphany
Tag: featured-epiphany
🧬 Moderna (NASDAQ: MRNA) Stock Analysis: Why We Still Believe This mRNA Pioneer Is Undervalued
Moderna has already doubled from its 2025 lows, yet we believe the story is still in its early chapters. Science Day confirmed that Moderna is becoming far more than a vaccine company—it's building one of biotechnology's most ambitious programmable medicine platforms.
🦸♂️ The Attic of the Soul: Why Your $9M “Super Moment” Is Covered in Dust
A dusty attic revealed a $9.1M treasure. Most of us have something similar—buried ideas, talents, or ambitions waiting to be rediscovered. The question is: will you climb the ladder?
S&P 500 PE Ratio Hits 30: Is a 2026 Bear Market Black Swan Immersion Imminent?
With the S&P 500 trading at nearly twice its historical P/E average, valuations are stretched. Even a 20% drop wouldn’t make stocks cheap. Is 2026 the year gravity reasserts itself?
No Bullish Trigger: Ginkgo Bioworks Should Read “Ginkgo Bio… Doesn’t Work”
Ginkgo Bioworks (DNA) has ambitious science and flashy AI rhetoric — but declining revenues, deep losses, and no insider conviction make this a tough stock to love. 🧬📉
Match Group (MTCH) Update: CEO Keeps Swiping Buy + Hinge Still Crushing It
Spencer Rascoff is swiping right on Match Group. With Hinge outpacing Tinder, free cash flow flowing, and big-name funds saying “I do,” is this the rebound stock your portfolio’s been hoping for?